At-Home ApoB Test

What It Measures

ApoB measures Apolipoprotein B-100 (ApoB), reported in mg/dL or g/L. Each atherogenic lipoprotein particle carries exactly one molecule of ApoB-100. Therefore, ApoB concentration directly equals lipoprotein particle count — unlike LDL-C, which estimates cholesterol mass and can misclassify risk when particles are small and dense.

Reference ranges: ApoB below 80 mg/dL is optimal (some guidelines use <70 for high-risk patients); 80–99 is near-optimal; 100–129 is borderline high; ≥130 is high. Sources: Sniderman AD et al. (PMID: 21600519); ESC/EAS Guidelines (PMID: 31504418).

Why ApoB and LDL-C can disagree: A patient with triglycerides of 250 mg/dL and LDL-C of 110 mg/dL may have an ApoB of 130 mg/dL — placing them in 'high' risk despite an apparently borderline LDL-C. This discordance is common in metabolic syndrome and type 2 diabetes.

Why It Matters for Longevity

A 2021 meta-analysis (Bjornsson E et al., Atherosclerosis, PMID: 33892285) found that ApoB provided superior discrimination for major adverse cardiovascular events vs. LDL-C, particularly in individuals with elevated triglycerides and low LDL-C.

The 2019 ESC/EAS dyslipidemia guidelines (Mach F et al., Eur Heart J, 2020, PMID: 31504418) state that ApoB is an 'accurate measure of the burden of atherogenic lipoproteins' and recommend its use as an alternative to LDL-C, particularly in patients with elevated triglycerides, diabetes, obesity, or metabolic syndrome.

Mechanistically, atherogenesis requires penetration of ApoB-containing lipoprotein particles into the arterial wall. Particle count — measured directly by ApoB — is what drives this process. This is the biological rationale for why ESC/EAS guidelines and many cardiologists endorse ApoB as a superior alternative marker to LDL-C for risk stratification, particularly in patients with metabolic syndrome, elevated triglycerides, or insulin resistance.

Top Providers Compared

LetsGetChecked Heart Health Advanced (~$129 verify on site): ApoB + full lipid panel, dried blood spot, 2–5 days, CLIA-certified. Caveat: LetsGetChecked ApoB is bundled into advanced panels in the US — confirm current panel composition on site.

Ulta Lab Tests — Apolipoprotein B (~$39–59 verify on site): ApoB standalone, venipuncture, 1–2 days, CLIA-certified (LabCorp).

Walk-In Lab — ApoB (~$49 verify on site): ApoB standalone, venipuncture, 1–2 days, CLIA-certified (Quest). No affiliate.

Pricing note: All prices are approximate starting prices as of drafting date. Verify current pricing on each provider's website.

How to Interpret Your Results

This is a general reference framework. ApoB interpretation depends heavily on your other cardiovascular risk factors. This content does not constitute individualized medical advice.

ApoB below 80 mg/dL: Optimal range by most current guidelines. Some high-risk patients (established cardiovascular disease or familial hypercholesterolemia) are targeted below 60–70 mg/dL by their cardiologist.

ApoB 80–99 mg/dL: Near-optimal. In context of other risk factors (smoking, hypertension, diabetes, family history), this level may still warrant discussion with a physician.

ApoB 100–129 mg/dL: Overlaps with ACC/AHA 'borderline' cardiovascular risk category. Lifestyle optimization and reassessment are typically the first line. Medication decisions depend on your overall risk score.

ApoB ≥130 mg/dL: Associated with high cardiovascular risk. Physician consultation strongly recommended. Statin therapy along with lifestyle modification is commonly discussed at this level.

Talk to your doctor: An ApoB result in isolation cannot determine cardiovascular risk or guide treatment. Your physician will contextualize it against blood pressure, family history, glycemic status, and 10-year ASCVD risk calculation.

Sample Prep and Accuracy Notes

Fasting required? Generally yes for consistency, though ApoB itself is less sensitive to recent meals than triglycerides. Most providers request overnight fasting so the full panel run alongside ApoB is accurate.

ApoB assay standardization: ApoB assays are well-standardized across clinical laboratories using immunoturbidimetric or immunonephelometric methods. Coefficient of variation within well-run labs is typically below 3% — an advantage over calculated LDL-C.

Dried blood spot ApoB: Fewer validation studies exist for dried blood spot ApoB compared to 25(OH)D or lipid panels. For highest accuracy, venipuncture through Quest or LabCorp is preferred.

Conditions affecting ApoB: Familial hypercholesterolemia (very high ApoB); hypothyroidism (elevated); liver disease (may lower ApoB production); high-dose niacin, fibrates, statins (lower ApoB).

Frequently Asked Questions

Is ApoB better than LDL-C for cardiovascular risk? In most studies, ApoB is an equal or superior predictor of cardiovascular events compared to LDL-C, particularly in individuals with metabolic syndrome, elevated triglycerides, or type 2 diabetes. Both markers are recommended by current cardiovascular guidelines; ApoB is increasingly endorsed as a preferred secondary or alternative marker.

Does insurance cover ApoB testing? ApoB testing (CPT code 82172) is covered by many health insurance plans when ordered by a physician with a relevant diagnosis code. Medicare does not currently cover ApoB as a routine screening test independent of physician order.

What does it mean if my LDL-C is normal but ApoB is high? This discordance most commonly occurs in individuals with elevated triglycerides, small dense LDL phenotype, or insulin resistance. It indicates more atherogenic lipoprotein particles than your LDL-C suggests — an important finding to share with your physician.

How often should I test ApoB? If ApoB is within optimal range and you are not on lipid-lowering therapy, annual testing is reasonable. If on statins or other lipid-lowering medication, testing every 3–6 months until stable is typically recommended.

References

1. Sniderman AD et al. Concordance/Discordance Between Plasma ApoB and LDL-Cholesterol and NonHDL-Cholesterol and the Risk of Cardiovascular Events. J Clin Lipidol. 2011;5(3):182-188. PMID: 21600519.

2. Mach F et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2020;41(1):111-188. PMID: 31504418.

3. Bjornsson E et al. ApoB versus LDL-C for predicting cardiovascular events: a systematic review and meta-analysis. Atherosclerosis. 2021;322:12-19. PMID: 33892285.